SEC Form S-8 filed by Leap Therapeutics Inc.
As filed with the Securities and Exchange Commission on March 26, 2025
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
Under
The Securities Act of 1933
Leap Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
Delaware | 27-4412575 |
(State or other jurisdiction of incorporation or organization) |
(IRS Employer Identification No.) |
47 Thorndike Street
Suite B1-1
Cambridge, MA 02141
Telephone: (617) 714-0360
(Address of principal executive offices) (Zip Code)
Leap Therapeutics, Inc. 2016 Equity Incentive Plan
(Full title of the Plan)
Douglas E. Onsi
Chief Executive Officer and President
Leap Therapeutics, Inc.
47 Thorndike Street, Suite B1-1
Cambridge, MA 02141
(Name and address of agent for service)
(617) 714-0360
(Telephone number, including area code, of agent for service)
Copy to:
Julio E. Vega, Esq.
Morgan, Lewis & Bockius LLP
One Federal Street
Boston, MA 02110
(617) 951-8000
Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer ¨ | Accelerated filer ¨ |
Non-accelerated filer x | Smaller reporting company x |
Emerging growth company ¨ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨
INCORPORATION OF DOCUMENTS BY REFERENCE
This Registration Statement on Form S-8, relating to the Leap Therapeutics, Inc. 2016 Equity Incentive Plan, is being filed for the purpose of registering additional securities of the same class as other securities for which a Registration Statement on Form S-8 has previously been filed and is effective. Pursuant to General Instruction E to Form S-8, except as otherwise set forth below, this Registration Statement incorporates by reference the contents of the following Registration Statements on Form S-8 previously filed by the Registrant with the Securities and Exchange Commission (the “Commission”):
· | Registration Statement on Form S-8, File No. 333-215787, filed on January 27, 2017; |
· | Registration Statement on Form S-8, File No. 333-223707, filed on March 16, 2018; |
· | Registration Statement on Form S-8, File No. 333-232066, filed on June 11, 2019; |
· | Registration Statement on Form S-8, File No. 333-237295, filed on March 20, 2020; |
· | Registration Statement on Form S-8, File No. 333-254360, filed on March 16, 2021; |
· | Registration Statement on Form S-8, File No. 333-262409, filed on January 28, 2022; |
· | Registration Statement on Form S-8, File No. 333-269586, filed on February 6, 2023; and |
· | Registration Statement on Form S-8, File No. 333-276726, filed on January 26, 2024. |
Part II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 8. | Exhibits. |
Exhibit Number | Exhibit |
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Cambridge, Commonwealth of Massachusetts on March 26, 2025.
LEAP THERAPEUTICS, INC. | ||
By: | /s/ Douglas E. Onsi | |
Name: | Douglas E. Onsi | |
Title: | Chief Executive Officer and President |
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Christopher Mirabelli and Douglas Onsi, and each of them, as his true and lawful attorney-in-fact and agent with full power of substitution, for him in any and all capacities, to sign any and all amendments to this registration statement (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the SEC, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
Signature | Title | Date | ||
/s/ Douglas E. Onsi | Chief Executive Officer, President, Chief Financial Officer and Director (Principal Executive Officer and Principal Financial and Accounting Officer) | March 26, 2025 | ||
Douglas E. Onsi | ||||
/s/ Christopher K. Mirabelli | Director and Chair | March 26, 2025 | ||
Christopher K. Mirabelli | ||||
/s/ James Cavanaugh | Director | March 26, 2025 | ||
James Cavanaugh | ||||
/s/ Thomas Dietz | Director | March 26, 2025 | ||
Thomas Dietz | ||||
/s/ William Li | Director | March 26, 2025 | ||
William Li | ||||
/s/ Joseph Loscalzo | Director | March 26, 2025 | ||
Joseph Loscalzo | ||||
/s/ Patricia Martin | Director | March 26, 2025 | ||
Patricia Martin | ||||
/s/ Nissim Mashiach | Director | March 26, 2025 | ||
Nissim Mashiach | ||||
/s/ Christian Richard | Director | March 26, 2025 | ||
Christian Richard | ||||
/s/ Richard L. Schilsky | Director | March 26, 2025 | ||
Richard L. Schilsky |